Sumitomo Dainippon Pharma Co., Ltd.
46 articles with Sumitomo Dainippon Pharma Co., Ltd.
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., and Myovant Sciences announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash.
Myovant Sciences formed a special committee of independent directors to assess Sumitovant Biopharma's offer after Sumitovant announced plans to acquire the company.
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
Myovant Sciences Ltd. confirmed that it has received a preliminary, non-binding proposal from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash.
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
Jazz Pharmaceuticals plc and Sumitomo Pharma Co., Ltd. announced that the companies have entered into an exclusive licensing agreement under which Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma's investigational DSP-0187.
Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma
Sumitomo Dainippon Pharma Oncology, Inc. announced that the Phase 3 WIZARD 201G study will terminate following its second interim analysis after determining there is a low probability of meeting the primary endpoint of overall survival at the final analysis.
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
Her career as a physician and scientist is guided by a combination of logic and creativity.
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma
Sumitomo Dainippon Pharma Oncology, Inc. today announced that the first patient has been dosed in the Phase 1 dose expansion portion of the study evaluating the investigational agent TP-1287
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Study of DSP-0390 in Patients with Recurrent High-Grade Glioma
Sumitomo Dainippon Pharma Oncology, Inc. today announced the first patient has been dosed in a Phase 1 study evaluating its investigational agent DSP-0390, an emopamil-binding protein (EBP) inhibitor
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
Sunovion Pharmaceuticals Inc.,its parent company Sumitomo Dainippon Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront, non-racemic ratio of amisulpride enantiomers, SEP-378614 and SEP-380135.
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.
Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, and Sumitomo Dainippon Pharma Co., Ltd., announced that a new drug application for TWYMEEG® Tablets 500mg3 : Imeglimin hydrochloride), for the treatment of type 2 diabetes, was approved in Japan on June 23.
Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States.
Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021
Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, presented new findings on a range of investigational agents from the company's pipeline at the American Association for Cancer Research Virtual Annual Meeting I, taking place April 10-15, 2021.
Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 2 Zella 201 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Acute Myeloid Leukemia at 62nd ASH Annual Meeting
Additional Presentations Provide Updates on Development Programs for Investigational Agents TP-3654 and Dubermatinib
Drawbridge Health Announces Partnerships to Fuel Expansion in Japan
Drawbridge Health, a healthcare technology company redefining the blood draw experience for both patients and healthcare providers, announced a further investment from Sumitomo Dainippon Pharma Co., Ltd. as well as a new research and development collaboration agreement.
Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Dubermatinib at ESMO 2020 Virtual Annual Congress
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data evaluating the oral investigational agent dubermatinib (TP-0903), an AXL kinase inhibitor, will be presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
Collaboration to Focus on Rare Genetic and Demyelinating Diseases, Including Lysosomal Storage Diseases